Arcellx, Inc. (ACLX)
NASDAQ: ACLX · IEX Real-Time Price · USD
55.50
-1.38 (-2.43%)
At close: Dec 29, 2023, 4:00 PM
55.49
-0.01 (-0.02%)
After-hours: Dec 29, 2023, 4:13 PM EST
Arcellx Employees
Arcellx had 98 employees on December 31, 2022. The number of employees increased by 20 or 25.64% compared to the previous year.
Employees
98
Change (1Y)
20
Growth (1Y)
25.64%
Revenue / Employee
$481,337
Profits / Employee
-$1,321,694
Market Cap
2.70B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 98 | 20 | 25.64% |
Dec 31, 2021 | 78 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Patterson Companies | 7,600 |
Premier | 2,800 |
Zai Lab | 2,036 |
Galapagos NV | 1,338 |
Privia Health Group | 964 |
GoodRx Holdings | 954 |
Intellia Therapeutics | 598 |
Rocket Pharmaceuticals | 240 |
ACLX News
- 23 days ago - Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH - PRNewsWire
- 6 weeks ago - Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium - Market Watch
- 6 weeks ago - Kite and Arcellx Announce Expansion in Strategic Partnership - Business Wire
- 6 weeks ago - ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP - PRNewsWire
- 6 weeks ago - Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights - PRNewsWire
- 2 months ago - Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition - PRNewsWire
- 2 months ago - Arcellx to Participate in Two Upcoming Investor Conferences - PRNewsWire
- 4 months ago - Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results - PRNewsWire